Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accumulated Expenses (2016 - 2025)

UroGen Pharma (URGN) has disclosed Accumulated Expenses for 10 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 27.87% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2025, up 27.87%, and an annual FY2025 reading of $13.5 million, up 27.87% over the prior year.
  • Accumulated Expenses was $13.5 million for Q4 2025 at UroGen Pharma, up from $11.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.5 million in Q4 2025 and bottomed at $4.7 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $7.8 million, with a median of $6.9 million recorded in 2021.
  • Peak annual rise in Accumulated Expenses hit 1905.11% in 2021, while the deepest fall reached 27.28% in 2021.
  • Year by year, Accumulated Expenses stood at $6.9 million in 2021, then increased by 18.84% to $8.3 million in 2022, then soared by 30.97% to $10.8 million in 2023, then fell by 2.26% to $10.6 million in 2024, then grew by 27.87% to $13.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for URGN at $13.5 million in Q4 2025, $11.1 million in Q3 2025, and $11.6 million in Q2 2025.